GSK宣布将在英国剑桥生物医学园区建立一座大型全球研发中心

28 July 2026--GSK plc (LSE/NYSE: GSK) today announced plans to establish a major new global R&D centre in Cambridge, UK, as part of the company’s plan to accelerate its R&D pipeline. The new 300,000 square foot site, on the Cambridge Biomedical Campus in the heart of the UK’s life sciences “Golden Triangle,” will be home to GSK’s R&D operations in the UK and more than 1,000 GSK scientists.

The Cambridge Biomedical Campus is one of the largest biomedical campuses in Europe. The new location will provide GSK scientists with direct access to a world-class ecosystem of biomedical research, patient care and academia, enabling translational research by bridging laboratory science with clinical practice.

The GSK site will feature state-of-the-art, tech-enabled labs and infrastructure to support research in the company’s focus areas of Oncology, Respiratory, Hepatology, Vaccines and HIV.

The Cambridge Biomedical Campus is home to more than 22,000 people working in life sciences, with more than 37,000 people visiting every day. More than 1 million patients are treated on the campus every year, and over 470 biopharma/ biotech and AI companies are located there. These include many existing GSK partners and collaborations, such as, the Cambridge Centre for Data-Driven Discovery; Cambridge-GSK Translational Immunology Collaboration; Cambridge-GSK Metabolic Science Collaboration; Cambridge Immune Ageing; GSK-Teichmann Lab; and GSK’s Clinical Unit at Addenbrooke’s Hospital.

Luke Miels, Chief Executive Officer, GSK, said: “This investment will accelerate our R&D and help us deliver new, competitive products. It integrates GSK further into one of the world’s leading centres of knowledge and demonstrates the attractiveness of the UK’s life sciences ecosystem.”

Tony Wood, Chief Scientific Officer, GSK, said: “Cambridge has built one of the world’s best life sciences ecosystems, with leading universities, hospitals and biotech companies. The campus provides exceptional opportunities for collaboration. With our existing connections and experience, we see this move as a catalyst for faster, bolder medicines discovery by accelerating the science that matters most for GSK's next wave of medicines.”

The site in Cambridge, currently in development by Prologis, will be part of GSK’s wider UK network of collaboration with leading academic institutions and pioneering scientific organisations, including the University of Oxford, Kings College London, Imperial College, the University of Manchester, Wellcome and the Crick Institute.

As a result of the planned move to Cambridge, GSK will vacate its R&D site at Stevenage, Hertfordshire, with a phased move for employees by 2029. Alongside the move to Cambridge, GSK will also upgrade its existing R&D laboratories at Ware in Hertfordshire and move some employees there to create a fully integrated drug development and commercial manufacturing scale up capability. Overall, the company plans to invest £400 million over 3 years in support of these changes.

GSK will retain its global headquarters in London, which is unaffected by today’s announcement.

GSK invests over £6 billion in R&D every year of which more than £1.5 billion is in the UK.